Olema Pharmaceuticals (OLMA): Price and Financial Metrics
OLMA Price/Volume Stats
| Current price | $5.66 | 52-week high | $16.77 |
| Prev. close | $5.28 | 52-week low | $4.60 |
| Day low | $5.24 | Volume | 1,699,200 |
| Day high | $5.79 | Avg. volume | 1,424,564 |
| 50-day MA | $8.08 | Dividend yield | N/A |
| 200-day MA | $10.89 | Market Cap | 324.31M |
OLMA Stock Price Chart Interactive Chart >
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
OLMA Price Returns
| 1-mo | -7.21% |
| 3-mo | -52.48% |
| 6-mo | -61.47% |
| 1-year | -50.22% |
| 3-year | -4.87% |
| 5-year | N/A |
| YTD | -2.92% |
| 2024 | -58.45% |
| 2023 | 472.65% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |
Loading social stream, please wait...